These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 10645045

  • 41. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM, Califf RM, Topol EJ.
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [Abstract] [Full Text] [Related]

  • 42. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003 Apr; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 43. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V, Marques AM, Oliveira H, Ramos D, Lopes P, Camacho M, Gonsalves A.
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [Abstract] [Full Text] [Related]

  • 44. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ.
    Am J Cardiol; 1997 Feb 01; 79(3):286-91. PubMed ID: 9036746
    [Abstract] [Full Text] [Related]

  • 45. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P, Cohen EA, Batchelor W, Lazzam C, Kreatsoulas C, Natarajan MK, Strauss BH.
    Am Heart J; 2001 Feb 01; 141(2):218-25. PubMed ID: 11174335
    [Abstract] [Full Text] [Related]

  • 46. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP, Walters DL, Aroney CN.
    Int J Cardiol; 2006 Apr 28; 109(1):16-20. PubMed ID: 16014315
    [Abstract] [Full Text] [Related]

  • 47. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ, Kereiakes DJ, Adgey AA, Fox KA, Hillegass WB, Pfisterer M, Vassanelli C.
    Eur Heart J; 1998 Apr 28; 19 Suppl D():D40-51. PubMed ID: 9597521
    [Abstract] [Full Text] [Related]

  • 48. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators.
    Am Heart J; 2001 Mar 28; 141(3):402-9. PubMed ID: 11231437
    [Abstract] [Full Text] [Related]

  • 49. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R, Haubelt H, Bechtloff S, Schneider S, Frilling B, Rustige J, Marsalek P, Seidl K, Senges J, Hellstern P.
    Herz; 2003 Aug 28; 28(5):445-52. PubMed ID: 12928744
    [Abstract] [Full Text] [Related]

  • 50. Bridge to operation with the GPIIb/IIIa inhibitor abciximab in high-risk coronary patients.
    Schoenhoff F, Kayhan N, Thomas G, Haase KK, Borggrefe M, Katus HA, Hagl S, Vahl CF.
    Thorac Cardiovasc Surg; 2006 Apr 28; 54(3):150-6. PubMed ID: 16639674
    [Abstract] [Full Text] [Related]

  • 51. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ.
    Am J Cardiol; 1996 May 15; 77(12):1045-51. PubMed ID: 8644655
    [Abstract] [Full Text] [Related]

  • 52. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA, Lincoff AM.
    Int J Clin Pract; 2003 May 15; 57(1):43-8. PubMed ID: 12587942
    [Abstract] [Full Text] [Related]

  • 53. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2001 Nov 15; 142(5):790-8. PubMed ID: 11685164
    [Abstract] [Full Text] [Related]

  • 54. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE.
    Am Heart J; 2001 Feb 15; 141(2):226-33. PubMed ID: 11174336
    [Abstract] [Full Text] [Related]

  • 55. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1998 May 19; 97(19):1912-20. PubMed ID: 9609084
    [Abstract] [Full Text] [Related]

  • 56. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
    Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW.
    Am Heart J; 2000 Oct 19; 140(4):603-10. PubMed ID: 11011333
    [Abstract] [Full Text] [Related]

  • 57. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
    Cho L, Bhatt DL, Wolski K, Lincoff M, Topol EJ, Moliterno DJ.
    Am Heart J; 2001 Apr 19; 141(4):599-602. PubMed ID: 11275926
    [Abstract] [Full Text] [Related]

  • 58. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
    Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA.
    Am Heart J; 1999 Jul 19; 138(1 Pt 1):49-54. PubMed ID: 10385763
    [Abstract] [Full Text] [Related]

  • 59. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
    Di Pasquale P, Cannizzaro S, Scalzo S, Maringhini G, Vitrano GM, Giubilato A, Giambanco F, Sarullo FM, Paterna S.
    Int J Cardiol; 2003 Dec 19; 92(2-3):265-70. PubMed ID: 14659863
    [Abstract] [Full Text] [Related]

  • 60. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
    Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, Stone GW, McClure R, Roffi M, Moliterno DJ, TARGET Investigators.
    Am J Cardiol; 2006 Jun 01; 97(11):1585-90. PubMed ID: 16728219
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.